On the final day of the Pharmabiotics Conference, described by Camille Bello, Communication and Membership Manager at Pharmabiotics Research Institute, as “the only microbiome conference of development and regulation,” the core message is that bringing microbiome-based innovations to market requires more than strong science—it also demands the ability to navigate complex regulatory pathways. Alongside a scientifically rich program, each speaker is asked to share where they stand in their regulatory journey, turning presentations into practical case studies for an industry still defining how to move microbiome innovations through regulatory systems. Within this framework, the PRI – Pharmabiotic Research Institute positions itself as the only microbiome regulatory science center, created to help companies accelerate time to market and reduce costs by supporting them through difficult regulatory processes. PRI outlines two main avenues of action: regulatory foresight, including a monthly newsletter for members, and an evidence-based advocacy effort it calls “scientific lobbying,” in which PRI and its members co-create scientific evidence to inform regulators about the technical specificities of the microbiome. The institute also emphasizes the value of scale: as the largest microbiome network in Europe, with more than 70 companies across the development chain, PRI argues that growing membership increases the weight and completeness of the scientific material produced—strengthening PRI’s role as a recognized stakeholder within European institutions and improving the quality of guidance it can provide both to members and to authorities. With more than 140 registrations for the 2026 edition, organizers closed by looking ahead to 2027 and inviting additional companies to join the community.